Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review by Kim, Jae Seok et al.
11926
Abstract. – OBJECTIVE: Hematologic can-
cer patients with Coronavirus Disease 2019 
(COVID-19) tend to have a more serious disease 
course than observed in the general population. 
Herein, we comprehensively reviewed existing 
literature and analyzed clinical characteristics 
and mortality of patients with hematologic ma-
lignancies and COVID-19.
MATERIALS AND METHODS: Through search-
ing PubMed until June 03, 2020, we identified 16 
relevant case studies (33 cases) from a total of 
45 studies that have reported on patients with 
COVID-19 and hematologic malignancies. We in-
vestigated the clinical and laboratory charac-
teristics including type of hematologic malig-
nancies, initial symptoms, laboratory findings, 
and clinical outcomes. Then, we compared those 
characteristics and outcomes of patients with 
hematologic malignancies and COVID-19 to the 
general population infected with COVID-19.
RESULTS: The median age was 66-year-old. 
Chronic lymphocytic leukemia was the most 
common type of hematologic malignancy 
(39.4%). Fever was the most common symp-
tom (75.9%). Most patients had normal leuko-
cyte counts (55.6%), lymphocytosis (45.4%), and 
normal platelet counts (68.8%). In comparison 
to patients with COVID-19 without underlying 
hematologic malignancies, dyspnea was more 
prevalent (45.0 vs. 24.9%, p=0.025). Leukocyto-
sis (38.9 vs. 9.8%, p=0.001), lymphocytosis (45.4 
vs. 8.2%, p=0.001), and thrombocytopenia (31.3 
vs. 11.4%, p=0.036) were significantly more prev-
alent and lymphopenia (18.2 vs. 57.4%, p=0.012) 
less prevalent in patients with hematologic ma-
lignancies. There were no clinical and labora-
tory characteristics predicting mortality in pa-
tients with hematologic malignancies. Mortali-
ty was much higher in patients with hematolog-
ic malignancies compared to those without this 
condition (40.0 vs. 3.6%, p<0.001).
CONCLUSIONS: Co-occurrence of hematolog-
ic malignancies and COVID-19 is rare. However, 
due to the high mortality rate from COVID-19 in 
this vulnerable population, further investigation 
on tailored treatment and management is re-
quired.
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Introduction
The novel coronavirus known as severe 
acute respiratory syndrome coronavirus 2 
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(SARS-CoV-2), causing coronavirus disease-19 
(COVID-19), has been rapidly spreading 
throughout the world since the first local out-
break in December 2019. While many peo-
ple with COVID-19 are asymptomatic or only 
have cold symptoms, such as fever and cough, 
some have severe clinical manifestations such 
as dyspnea, respiratory failure, and multiple or-
gan failure, leading to death1. Several studies2,3 
have suggested that this vulnerability to severe 
COVID-19 is associated with problems with 
genetic or type-1 interferons responses. Nev-
ertheless, many studies have still reported that 
older patients generally have poor prognosis in 
the clinical course of COVID-194.
Guan et al5 have revealed that COVID-19 pa-
tients with comorbidities have also poor clinical 
outcomes. Patients with hypertension, diabetes 
mellitus, and chronic obstructive pulmonary dis-
ease had a higher risk of exacerbation, and those 
with cardiovascular disease and cerebrovascular 
disease had more severe COVID-19 (i.e., admis-
sion to the intensive care unit requiring mechani-
cal ventilation, or death6).
Cancer is rare but a clinically important co-
morbidity among COVID-19 patients as those 
with cancer are more vulnerable to infection 
due to their systemic immunosuppressive state 
caused by malignancy itself or anticancer treat-
ments7. Liang et al8 have emphasized that can-
cer patients with COVID-19 have a higher risk 
of severe events and higher mortality than indi-
viduals without cancer. However, to our knowl-
edge, previous meta-analyses on cancer and 
COVID-19 mainly focused on solid tumors, not 
hematologic malignancies. Only few studies9,10 
have been reported on patients with hemato-
logic malignancies and these have been limited 
by a small number of cases. Due to the immu-
nodeficiency state of patients with hematologic 
malignancies such as leukemia, lymphoma, and 
multiple myeloma11, more research is needed to 
evaluate the clinical relationship between he-
matologic malignancies and COVID-19. To the 
best of our knowledge, there have been no com-
prehensive analyses of clinical characteristics 
and mortality in hematologic cancer patients 
with COVID-19. In this study, we aim to ana-
lyze the clinical and laboratory characteristics 
comprehensively, and mortality from existing 
case reports of hematologic malignancies with 
COVID-19, and to show the differences be-
tween patients with COVID-19 without hema-
tologic malignancies for the first time.
Materials and Methods
Search Strategy
We searched PubMed for case reports and 
series of COVID-19 patients with concomitant 
hematologic malignancies, including leukemia, 
lymphoma, and multiple myeloma, published 
until June 03, 2020. The search terms were as 
follows: (“COVID-19” OR “SARS-CoV-2” OR 
“2019-nCoV” OR “novel coronavirus 2019”) 
AND (“leukemia” OR “lymphoma” OR “multi-
ple myeloma”). Two of the authors (GEK and SK) 
screened the titles, abstracts, and full texts of the 
articles.
We included the following studies: (1) pa-
tients with laboratory or clinically confirmed 
COVID-19; (2) described concomitant hemato-
logic malignancy in infected patients. The ex-
clusion criteria were as follows: (1) studies not 
related to COVID-19 infection and hematolog-
ic malignancies; (2) review articles, protocols, 
guidelines, consensus, and comments; (3) full 
text of the article is inaccessible. Two reviewers 
(GEK and SK) separately executed the initial 
search, which yielded 45 articles published until 
June 03, 2020. This systematic review is report-
ed following the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Anal-
yses) statement12. We excluded 29 articles after 
reviewing the abstracts and full texts according 
to the exclusion criteria stated above: 3 were 
irrelevant, 10 were review articles, 13 were 
recommendations, and 2 were inaccessible. Fi-
nally, 16 articles that met the inclusion criteria 
for this systematic review were identified (a 
total of 33 cases). The detailed process of article 
selection is presented in Figure 1.
Data Extraction
From the 16 articles, two reviewers (GEK and 
SK) separately screened the titles, abstracts, and 
full texts to determine if they met the inclusion 
criteria. Then, two reviewers (GEK and SK) ex-
tracted the data independently and organized the 
information as follows: 1) study characteristics 
(journal title, author names, year of publication), 
2) population characteristics (patient age and 
sex, concomitant hematologic malignancies), 3) 
variables of interest (initial symptoms, laboratory 
findings, and clinical outcomes).
Data Analysis
The data extracted from the articles are 
presented in Supplementary Table I. We or-
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ganized the information, including the patient 
age and sex, concomitant hematologic malig-
nancies, initial symptoms, laboratory findings, 
and clinical outcomes. Then, we compared the 
clinical characteristics and mortality of pa-
tients with hematologic malignancies and the 
general population infected with COVID-1913. 
We used the χ2 test or Fisher’s exact test as a 
statistical method, Graphpad InStat 3 was used 
for statistical analyses.
Results
Baseline Characteristics of Patients 
with Hematologic Malignancies and 
COVID-19
In our study, 16 eligible articles were retrieved 
by the literature search, from which 33 cases of 
hematologic malignancies and COVID-19 were 
collected. The median age was 66 years. Eighteen 
male patients (54.5%) and 15 females (45.5%) 
were included (Table I). Chronic lymphocytic 
leukemia (CLL) was the most common type of 
hematologic malignancy (39.4%), followed by 
multiple myeloma (MM) (33.3%). Others were 
acute lymphoblastic leukemia, acute myeloid leu-
kemia, chronic myeloid leukemia, non-Hodgkin 
lymphoma, and Hodgkin lymphoma, all disease 
entities with fewer than 4 patients (Table I).
Initial Symptoms and Laboratory 
Features of Patients with Hematologic 
Malignancies and COVID-19
The most common symptoms were fever 
(75.9%), similar to that in patients without he-
matologic malignancies (83.3%). Next, cough 
was common (65.5%), followed by dyspnea 
(45.0%) and sore throat (14.0%) (Table II). In 
laboratory tests, a large proportion of patients 
had normal white blood cell counts (55.6%) and 
lymphocytosis (45.4%). Normal platelet counts 
were present in 68.8%. Nevertheless, most pa-
tients showed elevated levels of C-reactive pro-
tein (86.4%) (Table III).
CLL: chronic lymphocytic leukemia, MM: multiple myelo-
ma, NHL: non-Hodgkin lymphoma, ALL: acute lymphoblas-
tic leukemia, AML: acute myeloid leukemia, CML: chronic 
myeloid leukemia, HL: Hodgkin lymphoma.
Table I. Baseline characteristics of patients with hematologic 
malignancies and COVID-19.
 Age No. patients (%)
  (years) (N = 33) 
< 10 1 (3.0)
10-29 2 (6.1)
30-49 3 (9.1)
50-59 4 (12.1)
60-69 8 (24.2)
70-79 10 (30.3)
> 80 5 (15.2)
Median (min, max) 66 (4, 88)
Sex 
Male 18 (54.5)
Female 15 (45.5)
Types  
CLL 13 (39.4)
MM 11 (33.3)
NHL 3 (9.1)
ALL 2 (6.1)
AML 2 (6.1)
CML 1 (3.0)
HL 1 (3.0)
Figure 1. Flow chart of literature search.
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Comparisons of Clinical Characteristics 
According to Clinical Outcome of 
Patients with Hematologic Malignancies 
and COVID-19
Out of a total of 30 cases, excluding 3 cases 
that did not report clinical outcomes, 12 deaths 
were observed which corresponds to a fatality 
rate of 40%, while the other 18 patients recov-
ered from COVID-19. The recovery rate was 
60% (18 out of a total of 30 patients). In com-
parison with clinical characteristics according 
to clinical outcomes, there were no significant 
differences between recovery and death groups 
(Table II and III).
Comparisons of Clinical Characteristics 
between COVID-19 Patients with and 
without Hematologic Malignancies
The median age of patients from the case 
studies reporting hematologic malignancies and 
COVID-19 was 66 years (min 4, max 88), and 
thus, older than that of patients without hema-
Table II. Initial symptoms and comparisons between recovery and death groups in patients with hematologic malignancies and 
COVID-19.
 Symptoms (N = 29) Recovery (N = 15) Death (N = 11)
 No. (%)  No. (%) No. (%) p-value
Fever 22 (75.9) 12 (80.0)  9 (81.8) 1.000
Cough 19 (65.5) 11 (73.3)  5 (45.5) 0.228
Dyspnea 13 (45.0)  5 (33.3)  7 (63.6) 0.232
Sore throat  4 (14.0)  3 (20.0) 1 (9.1) 0.613
Others* 13 (45.0) – – –
*chest tightness (n=1), fatigue (n=8), epistaxis (n=1), chills (n=1), abdominal pain (n=1), vomiting (n=1), nausea (n=1), diarrhea 
(n=1), body aches (n=1), coryzal symptoms (n=1), ageusia (n=1), anosmia (n=1).
Table III. Laboratory findings and comparisons between recovery and death groups in patients with hematologic malignancies
and COVID-19.
 Laboratory findings  Recovery Death
 No. (%) No. (%) No. (%) p-value
WBC count N = 18 N = 9 N = 8 
Leukocytosis (> 15 000/µL)  7 (38.9) 2 (22.2) 5 (62.5) 0.153
Leukopenia (< 4 000/µL) 1 (5.5) 0 (0.0) 1 (12.5) 0.470
Abnormal (> 15 000 or < 4 000/µL)  8 (44.4) 2 (22.2) 6 (75) 0.056
Normal (4 000-15 000/µL) 10 (55.6) 7 (77.8) 2 (25) 0.056
Lymphocyte count N = 11 N = 4 N=6 
Lymphocytosis (> 4 800/µL)  5 (45.4) 1 (25) 4 (66.6) 0.523
Lymphopenia (< 1 000/µL)  2 (18.2) 1 (25) 1 (16.7) 1.000
Abnormal (> 4 800 or <1 000/µL)  7 (63.6) 2 (50) 5 (83.3) 0.500
Normal (1 000-4 800/µL)  4 (36.4) 2 (50) 1 (16.7) 0.500
Platelet count N = 16 N = 8 N = 7 
Thrombocytopenia (< 150 000/µL)  5 (31.2) 2 (25) 2 (28.6) 1.000
Normal (150 000-450 000/µL) 11 (68.8) 6 (75) 5 (71.4) 1.000
CRP N = 22 N = 13 N = 7 
Elevated (> 8 mg/L) 19 (86.4) 11 (84.6) 6 (85.7) 1.000
Normal (< 8 mg/L)  3 (13.6)  2 (15.4) 1 (14.3) 1.000
WBC: white blood cell, CRP: C-reactive protein.
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tologic malignancies (median 41, min 39, max 
72). The proportion of initial symptoms were 
comparable, but dyspnea was significantly more 
frequently reported in patients with hematologic 
malignancies (45.0 vs. 24.9%, p=0.025) (Table 
IV). Among laboratory tests, leukocytosis (38.9 
vs. 9.8%, p=0.001), lymphocytosis (45.4 vs. 8.2%, 
p=0.001), and thrombocytopenia (31.3 vs. 11.4%, 
p=0.036) were more frequent in patients with 
hematologic malignancies, while lymphopenia 
(18.2 vs. 57.4%, p=0.012) was significantly less 
frequent (Table IV). Among clinical outcomes, 
the mortality rate of patients with hematologic 
malignancies contracting COVID-19 was signifi-
cantly higher (40.0 vs. 3.6%, p<0.001) (Table IV).
Discussion
Older age and comorbid diseases such as dia-
betes, chronic pulmonary disease, and cardiovas-
cular disease are important risk factors for poor 
outcomes of COVID-196,14,15. Malignancies are al-
so considered a risk factor for severe COVID-195, 
but the true impact appears to be hidden due to 
low prevalence. According to epidemiologic stud-
ies of COVID-19, the prevalence of malignancy 
was estimated to be about 1~2%16-18, with the 
most common malignancy being lung cancer8. 
In the COVID-19 pandemic, cancer patients have 
several important issues. The first issue is the im-
munosuppressive state of cancer patients. Cancer 
patients have a significantly lower level of immu-
nity due to the malignancy itself or chemother-
apy11. They are vulnerable to infection and have 
a worse COVID-19 disease course and a higher 
mortality rate. The second issue is that cancer 
patients are often missing the scheduled treat-
ment approaches due to the risk of COVID-1918. 
They often cannot receive proper treatments be-
cause of limited medical resources focused on the 
COVID-19 pandemic, and deliberately delay the 
treatment plan due to increased risk of COVID-19 
by chemotherapy19. Ultimately, cancer patients 
comprise a very small proportion of COVID-19 
cases, but in reality, they are at high risk, so spe-
cial attention is required.
Hematologic malignancy has many clinical 
issues in the COVID-19 pandemic10,20-22. Unlike 
solid tumors, hematologic malignancy has more 
direct and negative effects on immunity as nor-
mal immune cells, which form the basic immune 
system, are replaced or inhibited by non-func-
tional tumor cells11. The immune dysfunction 
increases susceptibility to COVID-19 and makes 
the clinical course serious in hematologic cancer 
patients9. In addition, the treatments of hema-
tologic malignancies include a variety of potent 
immunosuppression, including hematopoietic 
stem cell transplantation. As a result, many he-
matologic cancer patients are forced to postpone 
timely treatment in the COVID-19 pandemic21,23.
In our study, the most common hematologic 
malignancy was CLL, followed by MM. The 
two diseases accounted for more than two-
thirds of hematologic malignancies. In contrast, 
Table IV. Comparisons of clinical and laboratory features with the patients without hematologic malignancies
  Patients with (N = 33) vs. without (N = 3600)
 Initial symptoms hematologic malignancies (%) p-value
Fever 75.9 vs. 83.3 0.412
Cough 65.5 vs. 60.3 0.704
Dyspnea 45.0 vs. 24.9 0.025*
Sore throat 14.0 vs. 12.3 0.810
Laboratory findings  
Leukocytosis 38.9 vs. 9.8 0.001*
Leukopenia 5.6 vs. 20.1 0.214
Lymphocytosis 45.4 vs. 8.2 0.001*
Lymphopenia 18.2 vs. 57.4 0.012*
Thrombocytopenia 31.3 vs. 11.4 0.036*
Elevated CRP 86.4 vs. 68.6 0.102
Mortality  
Death 40.0 vs. 3.6 < 0.001*
CRP: C-reactive protein, *p<0.05.
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one recent retrospective study of 39 patients 
with hematologic malignancies and COVID-19 
reported lymphoma as the most common tu-
mor24. However, we believe that the study has 
a limitation as a single center retrospective 
study in which the conclusions are not general. 
According to the Haematological Malignancy 
Research Network, which is a United Kingdom 
population-based patient cohort, CLL, and MM 
in the general population also show a higher 
prevalence compared to other types25. Thus, 
the high prevalence of CLL and MM among 
patients with COVID-19 seems to be attributed 
to such a pattern of prevalence in the general 
population. In particular, it is noteworthy that 
lymphoma has a high prevalence in the general 
population, while a few cases with COVID-19 
have been reported to date. Drawing conclusions 
on these preliminary reports is speculative, but 
we assume that the difference of negative effects 
on immunity according to the type of disease 
between leukemia and lymphoma may result in 
the difference of reported cases.
In patients with hematologic malignancies and 
COVID-19, the proportion of mild symptoms, such 
as fever, cough, and sore throat did not differ 
from the reported frequency in without hemato-
logic malignancies. However, patients with hema-
tologic malignancies had a larger proportion of 
dyspnea, suggesting that this patient group may 
have a more serious clinical course of COVID-19. 
Chen et al26 demonstrated that various hemato-
logic indices predict in-hospital death of a person 
with COVID-19. In this study, a specific range 
of the neutrophil-to-lymphocyte ratio, a decrease 
in platelet count, an increase in activated partial 
thromboplastin time, and D-dimer were associat-
ed with increased in-hospital death. In our study, 
hematologic cancer patients had high rates of 
leukocytosis and lymphocytosis, while a low rate 
of lymphopenia was observed. The findings, such 
as leukocytosis and lymphocytosis, are thought to 
reflect essential clinical features of abnormal pro-
liferation of lymphoid and myeloid tumor cells in 
hematologic malignancies. Jin et al10 emphasized 
that attention should be paid to the possibility 
that such laboratory features in hematologic ma-
lignancies may cause misdiagnosis by masking 
COVID-19, as continuous hematologic test ab-
normalities erase doubts about abnormal results 
caused by infection. Lymphopenia is a typical 
finding of COVID-191,4,13, and lymphopenia is re-
lated with a severe disease course and a potential 
predictor of poor prognosis27,28. However, absence 
of lymphopenia should not be considered as a sign 
of a mild disease form in patients with hemato-
logic malignancies. Thrombocytopenia is usually 
accompanied by diffuse intravascular coagulation 
and represents a serious condition in systemic 
infection. Thus, the high proportion of thrombocy-
topenia in patients with hematologic malignancies 
is in line with a severe form of COVID-19. Taken 
together, the laboratory constellation might be mis-
leading as patients with hematologic malignancies 
have typically leukocytosis and do not necessarily 
present with lymphopenia. We argue that moni-
toring the platelet count may be more informative 
about disease severity. This, however, needs to be 
observed in larger studies, which can be expected 
in the near future.
Our study indicated the very high mortality 
of the patients with hematologic malignancies 
compared to those without them, while there 
were no clinical and laboratory characteristics 
that were associated with clinical outcome. In 
this respect, a recent retrospective cohort study 
that involved a total of 536 patients with hemato-
logic malignancies contracting COVID-19 from 
66 hematology units, still showed the high stan-
dardized mortality ratio when compared with 
general population with COVID-19 as our study 
results. Moreover, the study demonstrated that 
older age, progressive disease, acute myeloid 
leukemia, non-Hodgkin lymphoma, plasma cell 
neoplasms, and severe COVID-19 predicted 
poor overall survival29.
It is important to interpret findings from the 
present study in light of its limitations. First, 
the small number of patients with hematologic 
malignancies and COVID-19 limits the general-
izability of our results. Nevertheless, we do not 
believe that the number of these subjects is small 
enough to reduce the credibility of the study. Oth-
er case studies except for a recent cohort study 
in Italy also included a small number of patients 
due to low incidence of hematologic malignancy. 
In addition, a recent large scale cohort study in 
Italy provided a valuable insight on risk factors 
for clinical outcome, while it could not show the 
details of clinical and laboratory characteristics 
as case studies including ours. Another limitation 
of our study is that the meta-analysis study of 
COVID-19, which served as a reference group, 
might include the patients with hematologic ma-
lignancies because some studies might not have 
reported pre-existing severe conditions such as 
hematologic malignancies. Nevertheless, in the 
meta-analysis study, the inclusion rate of malig-
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nancy might be very low at 1%13, and most are 
thought to be solid tumors, such as lung cancer8. 
Thus, it is unlikely that this limitation had a sub-
stantial impact on our presented results. Finally, 
despite our efforts, some case reports are continu-
ally being added, and our analysis may be limited 
in that respect. Nevertheless, our meta-analysis 
provides consistent and universal results for clin-
ical characteristics by analyzing heterogeneous 
individual case studies in a comprehensive way. 
To the best of our knowledge, we performed for 
the first time a comparative analysis with the in-
clusion of a recent meta-analysis study reporting 
COVID-19 in the general population. Therefore, 
we believe that our study provides meaningful re-
sults for patients with hematologic malignancies.
Conclusions
The present study shows that patients with he-
matologic malignancies are at high risk of severe 
form of COVID-19, given the poor outcome of cases 
reported to date. It further implies that laboratory 
results, including typical leukocytosis, absence of 
lymphopenia, and a higher percentage of thrombo-
cytopenia are different compared to patients without 
hematologic malignancies and should be interpreted 
with caution. Further studies are necessary to un-
derstand not only specific features of COVID-19 in 
patients with underlying hematologic malignancies 
but also to improve the survival rate of this hetero-
geneous group of patients.
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